NO20051664L - Behandling av demens og Parkinsons sykdom - Google Patents

Behandling av demens og Parkinsons sykdom

Info

Publication number
NO20051664L
NO20051664L NO20051664A NO20051664A NO20051664L NO 20051664 L NO20051664 L NO 20051664L NO 20051664 A NO20051664 A NO 20051664A NO 20051664 A NO20051664 A NO 20051664A NO 20051664 L NO20051664 L NO 20051664L
Authority
NO
Norway
Prior art keywords
disease
parkinson
dementia
treatment
methods
Prior art date
Application number
NO20051664A
Other languages
English (en)
Norwegian (no)
Inventor
Daniel W Gil
Larry A Wheeler
John E Donello
William G Tatton
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NO20051664L publication Critical patent/NO20051664L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
NO20051664A 2002-10-08 2005-04-04 Behandling av demens og Parkinsons sykdom NO20051664L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41703102P 2002-10-08 2002-10-08
PCT/US2003/031842 WO2004032934A1 (en) 2002-10-08 2003-10-07 Method of using (2-imidazolin-2-ylamino) qinoxalines in the treatment of dementia and parkinsons

Publications (1)

Publication Number Publication Date
NO20051664L true NO20051664L (no) 2005-05-31

Family

ID=32093952

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051664A NO20051664L (no) 2002-10-08 2005-04-04 Behandling av demens og Parkinsons sykdom

Country Status (20)

Country Link
US (1) US20040116436A1 (https=)
EP (1) EP1549314B1 (https=)
JP (1) JP2006504741A (https=)
KR (1) KR20050056235A (https=)
CN (1) CN100370988C (https=)
AT (1) ATE380551T1 (https=)
AU (2) AU2003279874A1 (https=)
BR (1) BR0314541A (https=)
CA (1) CA2501348A1 (https=)
DE (1) DE60318081T2 (https=)
ES (1) ES2297233T3 (https=)
HK (1) HK1080408B (https=)
IL (1) IL167848A (https=)
MX (1) MXPA05003665A (https=)
NO (1) NO20051664L (https=)
NZ (1) NZ539329A (https=)
PL (1) PL376347A1 (https=)
RU (1) RU2332218C2 (https=)
WO (1) WO2004032934A1 (https=)
ZA (1) ZA200502745B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7512436B2 (en) * 2004-02-12 2009-03-31 The Regents Of The University Of Michigan Method of evaluating metabolism of the eye
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100298305A1 (en) * 2008-11-26 2010-11-25 The United States Government, As Represented By The Department Of Veterans Affairs Tizanidine for the treatment of post-traumatic stress disorder and nightmares
DE102009043750A1 (de) * 2009-09-30 2011-08-04 Carl Zeiss Meditec AG, 07745 Verfahren und Vorrichtung zur Detektion von Ablagerungen im Auge
WO2016089997A1 (en) * 2014-12-02 2016-06-09 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
RU2680526C1 (ru) * 2016-07-05 2019-02-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Нейропротекторное средство, обладающее свойствами антиоксиданта и донатора оксида азота
US20210282643A1 (en) * 2016-08-01 2021-09-16 Cognoptix, Inc. System And Method For Detecting Tau Protein In Ocular Tissue

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
MX9709112A (es) * 1995-05-26 1998-02-28 Pfizer Combinacion para el tratamiento de parkinsonismo que contienen antagonistas selectivos de n-metil-d-aspartato.
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
JP4783502B2 (ja) * 1997-12-04 2011-09-28 アラーガン、インコーポレイテッド α２Ｂまたは２Ｂ／２Ｃアドレナリン受容体において作動剤様活性を示す置換イミダゾール誘導体
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
PL360707A1 (en) * 2000-07-14 2004-09-20 Allergan Inc. Compositions containing alpha-2-adrenergic agonist components

Also Published As

Publication number Publication date
AU2003279874A1 (en) 2004-05-04
HK1080408B (en) 2008-08-08
MXPA05003665A (es) 2005-06-08
ES2297233T3 (es) 2008-05-01
EP1549314B1 (en) 2007-12-12
JP2006504741A (ja) 2006-02-09
RU2332218C2 (ru) 2008-08-27
WO2004032934A1 (en) 2004-04-22
AU2010200730A1 (en) 2010-03-18
CN100370988C (zh) 2008-02-27
ZA200502745B (en) 2006-07-26
NZ539329A (en) 2007-11-30
DE60318081D1 (de) 2008-01-24
ATE380551T1 (de) 2007-12-15
KR20050056235A (ko) 2005-06-14
PL376347A1 (en) 2005-12-27
CN1703222A (zh) 2005-11-30
EP1549314A1 (en) 2005-07-06
HK1080408A1 (en) 2006-04-28
US20040116436A1 (en) 2004-06-17
CA2501348A1 (en) 2004-04-22
BR0314541A (pt) 2005-07-26
RU2005114505A (ru) 2005-10-27
IL167848A (en) 2010-11-30
DE60318081T2 (de) 2008-11-06

Similar Documents

Publication Publication Date Title
DE60132777D1 (de) Benzothiazolderivate zur behandlung von alzheimer und parkinson
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
DK0721449T3 (da) Inhibitorer af beta-amyloidproteinproduktion
ATE425750T1 (de) Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
NO20022531D0 (no) Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
DE60010702D1 (de) Behandlung von titanerz zur herstellung von titandioxidpigmenten
BR0214309A (pt) Derivados aril-1,4-pirazina substituìdos
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
ATE481093T1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
ATE384699T1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
NO20021541D0 (no) 5-beta-sapogenin- og pseudossapogeninderivater samt deres anvendelse ved behandling av demens
DE69926254D1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE427928T1 (de) Fluorobenzamide zur behandlung von alzheimer oder seniler dementia
IS8004A (is) Aðferð við meðhöndlun á vægri vitsmunaskerðingu og til að fyrirbyggja eða tefja Alzheimers-sjúkdóminn
NO20051664L (no) Behandling av demens og Parkinsons sykdom
WO2004026258A3 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease
ATE390134T1 (de) (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen
TW200503717A (en) Substituted 1,4-pyrazine derivatives
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
DE60327335D1 (de) Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application